NI201000031A - Derivados de ciclopropilamida. - Google Patents
Derivados de ciclopropilamida.Info
- Publication number
- NI201000031A NI201000031A NI201000031A NI201000031A NI201000031A NI 201000031 A NI201000031 A NI 201000031A NI 201000031 A NI201000031 A NI 201000031A NI 201000031 A NI201000031 A NI 201000031A NI 201000031 A NI201000031 A NI 201000031A
- Authority
- NI
- Nicaragua
- Prior art keywords
- cyclopropylamide
- derivatives
- derivative
- disclosed
- histamine
- Prior art date
Links
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical class NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 title abstract 4
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 1
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente, se divulga por lo menos un derivado de la ciclopropilamida, por lo menos una composición farmacéutica que contiene por lo menos un derivado de la ciclopropilamida divulgado en la presente y por lo menos un método para usar por lo menos un derivado de la ciclopropilamida divulgado en la presente para tratar por lo menos un trastorno asociado con el receptor H3 de la histamina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95718107P | 2007-08-22 | 2007-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201000031A true NI201000031A (es) | 2012-11-07 |
Family
ID=40279129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201000031A NI201000031A (es) | 2007-08-22 | 2010-02-22 | Derivados de ciclopropilamida. |
Country Status (36)
Country | Link |
---|---|
US (3) | US8063215B2 (es) |
EP (3) | EP2805937A1 (es) |
JP (1) | JP4691669B2 (es) |
KR (2) | KR20150076264A (es) |
CN (1) | CN101835750B (es) |
AR (1) | AR067996A1 (es) |
AU (1) | AU2008290329B2 (es) |
BR (1) | BRPI0815591B8 (es) |
CA (1) | CA2697256C (es) |
CO (1) | CO6260132A2 (es) |
CR (1) | CR11290A (es) |
CU (1) | CU23870B1 (es) |
CY (1) | CY1114805T1 (es) |
DK (1) | DK2195293T3 (es) |
DO (1) | DOP2010000062A (es) |
EA (2) | EA016687B8 (es) |
EC (1) | ECSP10010018A (es) |
ES (1) | ES2442926T3 (es) |
GT (1) | GT201000045A (es) |
HK (2) | HK1204606A1 (es) |
HN (1) | HN2010000352A (es) |
HR (1) | HRP20140047T1 (es) |
MX (1) | MX2010001679A (es) |
NI (1) | NI201000031A (es) |
NZ (1) | NZ584100A (es) |
PE (1) | PE20091077A1 (es) |
PH (1) | PH12013502616A1 (es) |
PL (1) | PL2195293T3 (es) |
PT (1) | PT2195293E (es) |
RS (1) | RS53144B (es) |
SA (1) | SA08290520B1 (es) |
SI (1) | SI2195293T1 (es) |
TW (2) | TWI432422B (es) |
UA (1) | UA101809C2 (es) |
WO (1) | WO2009024823A2 (es) |
ZA (1) | ZA201000885B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
WO2007150010A2 (en) | 2006-06-23 | 2007-12-27 | Abbott Laboratories | Cyclopropyl amine derivatives as histamin h3 receptor modulators |
RS53144B (en) | 2007-08-22 | 2014-06-30 | Astrazeneca Ab. | DERIVATES CYCLOPROPIL AMIDA |
TW200918527A (en) | 2007-09-06 | 2009-05-01 | Glaxo Group Ltd | Piperazine derivative having affinity for the histamine H3 receptor |
JP5771531B2 (ja) | 2009-02-02 | 2015-09-02 | エボテック・アーゲーEvotecAG | ヒスタミンh3受容体アンタゴニストとしてのアゼチジン |
TW201039825A (en) * | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
JP2013520414A (ja) * | 2010-02-18 | 2013-06-06 | アストラゼネカ・アクチエボラーグ | シクロプロピルベンズアミド誘導体の新規な結晶形態 |
SG183231A1 (en) * | 2010-02-18 | 2012-09-27 | Astrazeneca Ab | Solid forms comprising a cyclopropyl amide derivative |
US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
US10980806B2 (en) * | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
WO2022113008A1 (en) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
WO2023199091A1 (en) * | 2022-04-12 | 2023-10-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL297170A (es) * | 1963-04-04 | 1900-01-01 | ||
NL128365C (es) | 1963-11-05 | |||
US3449427A (en) * | 1965-06-03 | 1969-06-10 | Smithkline Corp | Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes |
US3697506A (en) | 1970-08-07 | 1972-10-10 | Pfizer | Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor |
US3686335A (en) * | 1970-12-21 | 1972-08-22 | Smith Kline French Lab | 5-vinyl-5h-di benzo(a,d)cycloheptenes |
US4432987A (en) | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
US4547505A (en) | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
CS244821B2 (en) | 1983-06-16 | 1986-08-14 | Boehringer Ingelheim Ltd | Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas |
DE3418167A1 (de) | 1984-05-16 | 1985-11-21 | Bayer Ag, 5090 Leverkusen | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen heteroaryloxyacetamiden |
DE3600288A1 (de) | 1986-01-08 | 1987-07-16 | Bayer Ag | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten |
DE3618004A1 (de) | 1986-05-28 | 1987-12-03 | Bayer Ag | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten |
WO1991009594A1 (en) | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
US5112818A (en) * | 1989-12-29 | 1992-05-12 | Banyu Pharmaceutical Co., Ltd. | 2-(2-cyclopropylpyrrolidin-4-ylthio)carbapenhem derivatives |
HUT66301A (en) | 1991-08-22 | 1994-11-28 | Monsanto Co | Safening herbicidal pyrazolylsufonylureas |
DE4131139A1 (de) | 1991-09-19 | 1993-03-25 | Bayer Ag | Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure |
CZ289332B6 (cs) | 1993-03-12 | 2002-01-16 | Pharmacia & Upjohn Company | Krystalická volná kyselina ceftiofuru, způsob její přípravy a farmaceutický prostředek s jejím obsahem |
CA2205998C (en) | 1994-11-23 | 2002-07-16 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5859246A (en) | 1997-01-30 | 1999-01-12 | Neurogen Corporation | 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands |
WO1998037077A1 (en) | 1997-02-24 | 1998-08-27 | Zymogenetics, Inc. | Calcitonin mimetics |
US6160134A (en) | 1997-12-24 | 2000-12-12 | Bristol-Myers Squibb Co. | Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines |
HUP0101810A3 (en) | 1998-01-27 | 2002-05-28 | Aventis Pharm Prod Inc | Substituted oxoazaheterocyclyl factor xa inhibitors and pharmaceutical compositions containing them |
US6268367B1 (en) | 1998-02-23 | 2001-07-31 | Zymogenetics, Inc. | Piperazine derivatives for treating bone deficit conditions |
WO2000000492A1 (fr) | 1998-06-26 | 2000-01-06 | Chugai Seiyaku Kabushiki Kaisha | DERIVE D'ACIDE L-α-AMINOADIPIQUE EN POUDRE FINE, PREPARATIONS SOLIDES ORALES CONTENANT LEDIT DERIVE ET PROCEDE DE TRAITEMENT DE POUDRES EN VRAC |
US6284761B1 (en) * | 1999-01-08 | 2001-09-04 | Neurogen Corporation | 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands |
CA2359989A1 (en) * | 1999-01-08 | 2000-07-13 | Xiaoyan Zhang | 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands |
AU5426500A (en) | 1999-06-16 | 2001-01-02 | Takeda Chemical Industries Ltd. | Benzazepine derivatives, process for the preparation of the same and uses thereof |
AU7715300A (en) | 1999-09-27 | 2001-04-30 | Merck & Co., Inc. | Method of preventing osteoporosis |
AU2930501A (en) | 2000-01-07 | 2001-07-24 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
CN1242989C (zh) | 2000-06-29 | 2006-02-22 | 艾伯特公司 | 芳基苯基环丙基硫醚衍生物及其作为抑制细胞粘附的抗炎和免疫抑制剂的用途 |
US6521619B2 (en) * | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
WO2002008221A2 (en) | 2000-07-20 | 2002-01-31 | Neurogen Corporation | Capsaicin receptor ligands |
WO2002051781A1 (fr) | 2000-12-25 | 2002-07-04 | Ajinomoto Co., Inc. | Procede permettant de preparer un compose d'halohydrine optiquement actif |
EA005974B1 (ru) | 2001-02-23 | 2005-08-25 | Мерк Энд Ко., Инк. | N-замещенные неарильные гетероциклические антагонисты nmda/nr2b |
WO2003004480A2 (en) | 2001-07-02 | 2003-01-16 | Novo Nordisk A/S | Substituted piperazine and diazepanes as histamine h3 receptor agonists |
EP1422228A1 (en) | 2001-08-08 | 2004-05-26 | Takeda Chemical Industries, Ltd. | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE |
JP2005508321A (ja) | 2001-09-26 | 2005-03-31 | メルク エンド カムパニー インコーポレーテッド | 結晶形態のエルタペネムナトリウム |
AU2002363236A1 (en) * | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
US6861432B2 (en) * | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
MXPA04009100A (es) | 2002-03-22 | 2004-12-06 | Lg Life Sciences Ltd | Nuevas formas cristalinas de (2s)- n-5- [amino (imino) metil]-2 -tienilmetil -1-(2r)- 2-[(carboximetil) amino] -3, 3-difenilpropanoil -2- pirrolidincarboxamida nh2o. |
WO2003103666A2 (en) | 2002-06-07 | 2003-12-18 | Altana Pharma Ag | Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones |
US20040077618A1 (en) | 2002-10-22 | 2004-04-22 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
US20040209858A1 (en) * | 2002-10-22 | 2004-10-21 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
JPWO2004046110A1 (ja) | 2002-11-15 | 2006-03-16 | アステラス製薬株式会社 | メラニン凝集ホルモン受容体拮抗剤 |
ATE384724T1 (de) | 2002-12-13 | 2008-02-15 | Smithkline Beecham Corp | Cyclopropylverbindungen als ccr5 antagonisten |
CA2523431A1 (en) | 2003-04-23 | 2004-11-25 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
WO2004098518A2 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Pyrazole-amide compounds useful as kinase inhibitors |
TWI339206B (en) * | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
RU2006125441A (ru) | 2003-12-15 | 2008-01-27 | Джапан Тобакко Инк. (Jp) | Производные циклопропана и их фармацевтическое применение |
ATE537830T1 (de) | 2004-07-06 | 2012-01-15 | Xenon Pharmaceuticals Inc | Nicotinamid derivate und ihre verwendung als therapeutika |
AR050865A1 (es) | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
NZ554722A (en) | 2004-09-29 | 2010-07-30 | Mitsubishi Tanabe Pharma Corp | 6-(Pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors |
EP1802307B1 (en) | 2004-10-15 | 2008-02-27 | Glaxo Group Limited | Pyrrolidine derivatives as histamine receptors ligands |
CA2591003A1 (en) | 2004-12-27 | 2006-07-06 | Astrazeneca Ab | Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders |
EP1844052A1 (en) | 2005-01-26 | 2007-10-17 | Pharmacia & Upjohn Company LLC | Thieno[2,3-d]pyrimidine compounds as inhibitors of adp-mediated platelets aggregation |
ATE517867T1 (de) | 2005-02-15 | 2011-08-15 | Glaxo Group Ltd | Verbindungen, die den glutamatrezeptor verstärken und anwendungen davon in der medizin |
PL2607362T3 (pl) | 2005-02-17 | 2015-05-29 | Astellas Pharma Inc | Karboksylany piperydyny i piperazyny jako inhibitory FAAH |
US20080176857A1 (en) | 2005-03-25 | 2008-07-24 | Michael Dalton Ennis | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors |
CA2602538A1 (en) | 2005-03-28 | 2006-10-05 | Pharmacia & Upjohn Company Llc | 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors |
CA2602227A1 (en) | 2005-03-28 | 2006-10-05 | Michael Dalton Ennis | 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors |
WO2006103544A2 (en) | 2005-03-28 | 2006-10-05 | Pharmacia & Upjohn Company Llc | 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors |
WO2007011623A1 (en) | 2005-07-15 | 2007-01-25 | Schering Corporation | Quinazoline derivatives useful in cancer treatment |
TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
CA2606004A1 (en) | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
PT1948607E (pt) | 2005-09-16 | 2010-06-02 | Janssen Pharmaceutica Nv | Ciclopropilaminas como moduladores do receptor h3 de histamina |
US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
CA2628187C (en) | 2005-10-31 | 2015-01-27 | Janssen Pharmaceutica N.V. | Novel processes for the preparation of cyclopropyl-amide derivatives |
CA2633653A1 (en) | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
WO2007076140A2 (en) | 2005-12-23 | 2007-07-05 | University Of Cincinnati | Treatment methods employing histamine h3 receptor antagonists, including betahistine |
EP1976840A1 (en) * | 2006-01-13 | 2008-10-08 | F.Hoffmann-La Roche Ag | Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators |
CN101384581B (zh) | 2006-02-17 | 2013-09-18 | 弗·哈夫曼-拉罗切有限公司 | 作为5ht2/d3调节剂的苯甲酰基-哌啶衍生物 |
SG170053A1 (en) | 2006-03-01 | 2011-04-29 | Cementech Pty Ltd | Matrix for masonry elements and method of manufacture thereof |
JP2009132621A (ja) | 2006-03-13 | 2009-06-18 | Ajinomoto Co Inc | シクロプロピルアミド化合物の製造方法 |
US7524848B2 (en) | 2006-03-23 | 2009-04-28 | Amgen Inc. | Diaza heterocyclic amide compounds and their uses |
US7834190B2 (en) | 2006-05-26 | 2010-11-16 | Kaneka Corporation | Process for production of optically active-3-amino-2-hydroxypropionic cyclopropylamide derivatives and salts thereof |
WO2007150010A2 (en) | 2006-06-23 | 2007-12-27 | Abbott Laboratories | Cyclopropyl amine derivatives as histamin h3 receptor modulators |
US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
CA2657702A1 (en) | 2006-07-03 | 2008-01-10 | Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek E N Patieentenzorg | Quinazolines and related heterocyclic comp0unds, and their therapeutic use |
US20090247499A1 (en) | 2006-08-21 | 2009-10-01 | Fletcher Joan M | Sulfonylated piperazines as cannabinoid-1 receptor modulators |
TW200828371A (en) | 2006-09-21 | 2008-07-01 | Matsushita Electric Ind Co Ltd | Chip-type filter |
DE102006056526A1 (de) | 2006-11-30 | 2008-06-05 | Archimica Gmbh | Verfahren zur stereoselektiven Synthese von chiralen Epoxiden durch ADH-Reduktion von alpha-Abgangsgruppen-substituierten Ketonen und Cyclisierung |
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
MX2009006781A (es) * | 2006-12-21 | 2010-01-15 | Neology Inc | Sistemas y métodos para una placa de metal habilitada con identificación por radio frecuencia. |
WO2008147864A2 (en) | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
EP2150115B1 (en) | 2007-05-23 | 2013-09-18 | Merck Sharp & Dohme Corp. | Cyclopropyl pyrrolidine orexin receptor antagonists |
ES2350511T3 (es) | 2007-06-11 | 2011-01-24 | F. Hoffmann-La Roche Ag | Derivados ciclohexilo. |
RS53144B (en) | 2007-08-22 | 2014-06-30 | Astrazeneca Ab. | DERIVATES CYCLOPROPIL AMIDA |
EP2207540B1 (en) | 2007-10-04 | 2014-02-26 | F. Hoffmann-La Roche AG | Cyclopropyl aryl amide derivatives and uses thereof |
TW200934772A (en) | 2008-01-15 | 2009-08-16 | Lilly Co Eli | Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide |
DE102008049371A1 (de) | 2008-03-06 | 2009-09-10 | Mühlbauer Ag | Einrichtung mit einem RFID-Transponder in einem elektrisch leitfähigen Gegenstand und Herstellungsverfahren hierfür |
WO2009135842A1 (en) | 2008-05-08 | 2009-11-12 | Evotec Neurosciences Gmbh | Azetidines and cyclobutanes as histamine h3 receptor antagonists |
JP2012503595A (ja) | 2008-07-28 | 2012-02-09 | シダンスク ユニバーシティ | 代謝病の治療用の化合物 |
CN101462980B (zh) | 2009-01-05 | 2013-01-09 | 扬州天辰精细化工有限公司 | 2,6—二氟苯甲酰胺的工业化生产方法 |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
JP2013520414A (ja) | 2010-02-18 | 2013-06-06 | アストラゼネカ・アクチエボラーグ | シクロプロピルベンズアミド誘導体の新規な結晶形態 |
SG183231A1 (en) | 2010-02-18 | 2012-09-27 | Astrazeneca Ab | Solid forms comprising a cyclopropyl amide derivative |
-
2008
- 2008-08-20 RS RS20140014A patent/RS53144B/en unknown
- 2008-08-20 TW TW097131744A patent/TWI432422B/zh active
- 2008-08-20 PL PL08788694T patent/PL2195293T3/pl unknown
- 2008-08-20 PT PT87886941T patent/PT2195293E/pt unknown
- 2008-08-20 EP EP14173061.4A patent/EP2805937A1/en not_active Withdrawn
- 2008-08-20 AU AU2008290329A patent/AU2008290329B2/en not_active Ceased
- 2008-08-20 NZ NZ584100A patent/NZ584100A/en not_active IP Right Cessation
- 2008-08-20 CA CA2697256A patent/CA2697256C/en active Active
- 2008-08-20 UA UAA201001119A patent/UA101809C2/uk unknown
- 2008-08-20 BR BRPI0815591A patent/BRPI0815591B8/pt active IP Right Grant
- 2008-08-20 SA SA08290520A patent/SA08290520B1/ar unknown
- 2008-08-20 JP JP2010521486A patent/JP4691669B2/ja not_active Expired - Fee Related
- 2008-08-20 KR KR1020157016290A patent/KR20150076264A/ko not_active Application Discontinuation
- 2008-08-20 EA EA201000204A patent/EA016687B8/ru not_active IP Right Cessation
- 2008-08-20 EA EA201200429A patent/EA201200429A1/ru unknown
- 2008-08-20 SI SI200831135T patent/SI2195293T1/sl unknown
- 2008-08-20 MX MX2010001679A patent/MX2010001679A/es active IP Right Grant
- 2008-08-20 EP EP10165133.9A patent/EP2253615B1/en active Active
- 2008-08-20 DK DK08788694.1T patent/DK2195293T3/da active
- 2008-08-20 KR KR1020107006086A patent/KR101588466B1/ko active IP Right Grant
- 2008-08-20 WO PCT/GB2008/050723 patent/WO2009024823A2/en active Application Filing
- 2008-08-20 CN CN2008801127426A patent/CN101835750B/zh active Active
- 2008-08-20 TW TW103103619A patent/TW201446748A/zh unknown
- 2008-08-20 ES ES08788694.1T patent/ES2442926T3/es active Active
- 2008-08-20 EP EP08788694.1A patent/EP2195293B1/en active Active
- 2008-08-21 AR ARP080103642A patent/AR067996A1/es unknown
- 2008-08-21 US US12/195,454 patent/US8063215B2/en not_active Expired - Fee Related
- 2008-08-22 PE PE2008001425A patent/PE20091077A1/es not_active Application Discontinuation
-
2010
- 2010-02-05 ZA ZA2010/00885A patent/ZA201000885B/en unknown
- 2010-02-15 CO CO10016765A patent/CO6260132A2/es active IP Right Grant
- 2010-02-22 DO DO2010000062A patent/DOP2010000062A/es unknown
- 2010-02-22 NI NI201000031A patent/NI201000031A/es unknown
- 2010-02-22 HN HN2010000352A patent/HN2010000352A/es unknown
- 2010-02-22 CR CR11290A patent/CR11290A/es unknown
- 2010-02-22 CU CU20100035A patent/CU23870B1/es not_active IP Right Cessation
- 2010-02-22 GT GT201000045A patent/GT201000045A/es unknown
- 2010-03-05 EC EC2010010018A patent/ECSP10010018A/es unknown
- 2010-12-01 HK HK15104865.7A patent/HK1204606A1/xx unknown
- 2010-12-01 HK HK10111208.3A patent/HK1144687A1/xx not_active IP Right Cessation
-
2011
- 2011-11-21 US US13/300,877 patent/US9029381B2/en active Active
-
2013
- 2013-12-16 PH PH12013502616A patent/PH12013502616A1/en unknown
-
2014
- 2014-01-15 CY CY20141100032T patent/CY1114805T1/el unknown
- 2014-01-15 HR HRP20140047AT patent/HRP20140047T1/hr unknown
-
2015
- 2015-04-13 US US14/685,536 patent/US20150216861A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201000031A (es) | Derivados de ciclopropilamida. | |
CU20140013A7 (es) | Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3 | |
ECSP088676A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
CL2011000957A1 (es) | Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer. | |
EA201100978A1 (ru) | Схема приема агониста рецептора s1p | |
BRPI0922301A2 (pt) | combinações de inibidor de hsp90 | |
CR20120001A (es) | Compuestos terapeuticos y composiciones | |
HN2011001247A (es) | Inhibidores de cinana akt y p70 s6 | |
AR065721A1 (es) | Derivados de piridazinona utiles como inhibidores de glucano sintasa. composiciones farmaceuticas. | |
PA8850801A1 (es) | Compuestos útiles para inhibir chk1 | |
CR20110029A (es) | Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina | |
CR20120008A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
CL2009001298A1 (es) | Compuestos derivados de n-ciclohexil-2-fenoxinicotinamida; composición farmcéutica que los comprende; combinación farmacéutica que los comprende; y su uso para tratar una enfermedad mediada por la pde4. | |
CL2009000803A1 (es) | Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada | |
ECSP099754A (es) | Derivados de la espirociclopropil piperidina | |
UY32258A (es) | Derivados de la espirociclobutilpiperidina | |
SV2009003368A (es) | Macrolidos | |
ATE481395T1 (de) | Cyclohexylderivate | |
AR052346A1 (es) | Composicion que comprende una epotilona y metodos para producir dicha composicion | |
CY1115587T1 (el) | Μεθοδος και συνθεση για την θεραπεια παθησης με την μεσολαβηση ενος ληπτη σεροτονινης (sεrοτονιν) | |
AR105791A2 (es) | Método para el tratamiento de biomasa | |
UY31303A1 (es) | Derivados de ciclopropil amida 978 | |
CY1114176T1 (el) | Παραγωγα κυκλοπροπυλαμιδιου που στοχευουν τον υποδοχεα η3 της ισταμινης |